MedPath

The comparison of metronidazole and the combination of metronidazole and probitic on treatment of bacterial vaginosis

Phase 2
Conditions
Bactetial Vaginosis.
Other specified inflammation of vagina and vulva
Registration Number
IRCT201106156807N1
Lead Sponsor
The Shahid Beheshti University of Medical Science & Health Service
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
90
Inclusion Criteria

1- bacterial vaginosis approval based on Amsel's criterias 2-married women aged 18-45 years 3-having one partner 4-absence of pregnancy and breast feeding 5-absence of mensturation at the time of attendance 6-not using vaginal drug, antibiotics and immonosupressive drugs since 14 days before starting the research 7-not having intercourse or using vaginal douche within the last 24 hours 8-absence of other types of candidias and trichmonas vaginitis at the time of study 9-not using alchohol , anticoagulant like comadin and disulfiram 10-absence of any diagnose medical disease such as diabetis , blood dyscrasia , thyroid disorders and liver disease by asking a patient 11-not using IUD. Exclusion criteria: 1-drug intolerancy 2-pregnancy during therapy 3-compulsion to use antibiotics

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Bactetial Vaginosis. Timepoint: Before treatment and after treatment. Method of measurement: Observation.
Secondary Outcome Measures
NameTimeMethod
Bactetial Vaginosis treatment. Timepoint: 3-7 days after treatment. Method of measurement: Observation.
© Copyright 2025. All Rights Reserved by MedPath